Ovation Science Inc. Closes Private Placement
Vancouver, BC, Las Vegas, NV – October 20, 2025 (CSE: OVAT | OTCQB: OVATF) – Ovation Science Inc. (“Ovation” or the “Company”), is pleased to announce that it has closed its previously announced non-brokered private placement financing of by issuing 3,167,000 units (each a “Unit”) at a price of $0.05 per Unit (the “Offering”) for total net proceeds of $158,350.
Under the Offering, each Unit consists of one common share (a “Share”) and one share purchase warrant (a “Warrant”). Each Warrant entitles the holder to purchase an additional Share at a price of $0.05 per share for a period of 24 months from the date of issue.
A director of the Company participated in the private placement and acquired 200,000 Units. This participation is considered a related party transaction under MI 61-101 but is exempt from the formal valuation and minority shareholder approval requirements pursuant to sections 5.5(b) and 5.7(1)(b), as the value of the transaction is less than 25% of the Company’s market capitalization.
The Units issued under the Offering are subject to a statutory hold period of four months and one day from the date of issuance.
In connection with the Offering, the Company paid eligible finders a cash fee equal to 8% of the gross proceeds raised from investors they introduced. In addition, the Company issued finder’s warrants equal to 8% of the number of Units subscribed for by those investors. Each finder’s warrant is exercisable to purchase one additional common share at a price of $0.05 per share for a period of 24 months from the date of issuance.
The proceeds of the Offering will be used to advance the business of the Company and for general working capital.
About Ovation Science Inc.
Ovation Science Inc. is a research and development company that develops topical and transdermal consumer products including its CBD/THC and other cannabinoid formulations which are licensed out and also distributed under Ovation’s own brands; ARLO CBD Beauty and InVibe® MD (“health & wellness” line); all made with its patented Invisicare® skin delivery technology. The Invisicare technology enhances the delivery of ingredients to and through the skin and is protected by patents and proprietary formulations which cannot be duplicated. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation’s management and science team have created a unique pipeline of over thirty proprietary medical / wellness topical and transdermal products along with a line of anti-aging / beauty formulas. Ovation earns revenues from royalties on licensees’ sales and the sale of Invisicare, along with revenue from its own product sales. Ovation has offices in Vancouver, BC Canada and Las Vegas, Nevada, USA.
Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward-looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.’s control.
Neither the Canadian Securities Exchange, OTC Markets nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
CORPORATE INQUIRIES:
Email: info@ovationscience.com
PH: 604-982-5700